Renowned molecular diagnostics provider Cepheid CPHD recently entered into a non-exclusive distribution agreement with Henry Schein Medical, the Medical business of one of the leading healthcare ...

Greetings stargazers. Occasionally, the calendar aligns so that I get to complain about daylight saving time in this column on the same weekend it goes into effect. I need to take the chance to do ...

Cepheid (NAS: CPHD) carries $32.2 million of goodwill and other intangibles on its balance sheet. Sometimes goodwill, especially when it's excessive, can foreshadow problems down the road. Could this ...

Cepheid CPHD recently launched its Xpert MRSA NxG assay in the commercial markets overseas, after the test won the CE-IVD status under the European Directive on In Vitro Diagnostic Medical Devices.

Following a high-profile pressure campaign, the company that makes a crucial tuberculosis test has agreed to sell its product at cost to an international organization that works with low-income ...

Cepheid's performance in the first quarter was driven by robust growth in clinical product sales resulting from test utilization in the emerging HAI test market for Xpert MRSA, continued adoption of ...

Danaher said on Tuesday it would buy molecular diagnostics company Cepheid in a deal valued at $4 billion, including debt, to strengthen its diagnostics unit. Danaher will pay Cepheid $53 per share in ...

This morning Bear Stearns put a $700 price target on shares of Google . But that's not the only stock getting a new stratospheric price target by an analyst. Michael Shulman is not Bear Stearns--he ...

Shares jump on the news that the company is being bought out by Danaher. Danaher has offered to by Cepheid for $4 billion in cash, valuing shares at $53 each. That represents a premium of 54% based on ...

On Sept. 10, Tom Gutshall and Kurt Petersen ran a little-known Sunnyvale biotech company specializing in life sciences research. While competing against a larger and more established rival, Cepheid ...

SUNNYVALE, Calif. (AP) -- Molecular diagnostics company Cepheid said Thursday it took a loss in the third quarter on costs related to a patent lawsuit. In late September Cepheid agreed to settle a ...

Shares of molecular diagnostics provider CepheidCPHD slumped 14.2% in after-hours trading yesterday, following the release of bleak preliminary results for its upcoming third quarter and revised full ...